Ginkgo Bioworks awarded $22.2M contract through BARDA BioMaP-Consortium

Ginkgo Bioworks (DNA) announced that it has been awarded a contract through the Biomedical Advanced Research and Development Authority’s, or BARDA, Biopharmaceutical Manufacturing Preparedness Consortium, or BioMaP-Consortium, to develop innovations that strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies, or mAbs, to protect against and treat infection by filoviruses such as Ebola, EBOV, and Sudan Viruses, or SUDV. The project has a total contract value of up to $22.2M and seeks to deploy these innovations to produce the anti-filovirus mAbs cocktail of 1C3 and 1C11, discovered and developed by Emory University. Ginkgo will lead a team composed of Advanced BioScience Laboratories Isolere Bio by Donaldson, NeuImmune and ProteoNic BV to develop and integrate innovative technologies that will span the entire process for producing mAb drugs. This project has been funded in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority.